See more : MarketEnterprise Co.,Ltd (3135.T) Income Statement Analysis – Financial Results
Complete financial analysis of Phoenix Life Sciences International Limited (PLSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phoenix Life Sciences International Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- enCore Energy Corp. (ENCUF) Income Statement Analysis – Financial Results
- FDG Kinetic Limited (0378.HK) Income Statement Analysis – Financial Results
- Shenzhen SEG Co.,Ltd (200058.SZ) Income Statement Analysis – Financial Results
- Telix Pharmaceuticals Limited (TLX.AX) Income Statement Analysis – Financial Results
- BB Seguridade Participações S.A. (BBSE3.SA) Income Statement Analysis – Financial Results
Phoenix Life Sciences International Limited (PLSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.phoenixlife.co
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited operates as a healthcare solutions company in the United States and internationally. The company focuses on advancing research, integrating programs, and manufacturing of products that target and treat diabetes, pain, and cancers, as well as address psychological, gastrointestinal, autoimmune, neurological, and sleep disorders. It offers oral soft gel capsules, thin film dissolvable strips, transdermal patches, sublingual oral sprays, suppositories, and topical creams. The company was formerly known as Stem Bioscience, Inc. and changed its name to Phoenix Life Sciences International Limited in May 2018. Phoenix Life Sciences International Limited was incorporated in 2009 and is headquartered in Las Vegas Nevada.
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 18.41K | 23.55K | 0.00 | 7.71K | -8.54K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 5.93K | 13.97K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 12.48K | 9.58K | 0.00 | 7.71K | -8.54K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 67.77% | 40.70% | 0.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 120.60K | 84.49K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.44M | 458.00 | 35.81K | 371.09K | 1.02M | 643.80K | 110.12K | 111.55K | 22.10K |
| Selling & Marketing | 124.26K | 0.00 | 0.00 | 14.95K | 240.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.56M | 458.00 | 35.81K | 386.04K | 1.26M | 643.80K | 110.12K | 111.55K | 22.10K |
| Other Expenses | 974.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -331.62K | -72.48K |
| Operating Expenses | 3.06M | 458.00 | 35.81K | 509.69K | 2.87M | 643.97K | 110.48K | -220.07K | -50.38K |
| Cost & Expenses | 3.06M | 458.00 | 35.81K | 515.63K | 2.88M | 643.97K | 110.48K | -220.07K | -50.38K |
| Interest Income | 3.00 | 0.00 | 0.00 | 4.03K | 2.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.44K | 83.06K | 139.21K | 184.20K | 621.06K | 22.10K | 20.60K | 12.86K | 0.00 |
| Depreciation & Amortization | 977.00 | 161.14K | 52.52K | 10.44K | 1.35M | 0.00 | 339.00 | 809.00 | 0.00 |
| EBITDA | -3.06M | -458.00 | -35.81K | -355.44K | -1.50M | -643.97K | -102.43K | -227.80K | -50.38K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,930.70% | -6,387.01% | 0.00% | -1,328.57% | 2,667.45% | 0.00% |
| Operating Income | -3.06M | -458.00 | -35.81K | -497.22K | -2.86M | -643.97K | -122.99K | -228.61K | -50.38K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -2,700.80% | -12,133.41% | 0.00% | -1,595.21% | 2,676.92% | 0.00% |
| Total Other Income/Expenses | -54.80K | -76.13K | -218.90K | -290.60K | -11.98M | 589.43K | -208.11K | 0.00 | 0.00 |
| Income Before Tax | -3.12M | -76.59K | -254.71K | -787.82K | -11.98M | -54.55K | -331.10K | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -4,279.30% | -50,854.25% | 0.00% | -4,294.44% | 0.00% | 0.00% |
| Income Tax Expense | 49.44K | 0.00 | 0.00 | 184.20K | 620.34K | 0.00 | 20.60K | 0.00 | 50.38K |
| Net Income | -3.12M | -76.59K | -254.71K | -787.82K | -11.97M | -54.55K | -331.10K | -228.61K | -50.38K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -4,279.30% | -50,851.19% | 0.00% | -4,294.44% | 2,676.92% | 0.00% |
| EPS | 0.00 | -2.46 | -8.63 | -28.81 | -1.06K | -8.66 | -42.45 | -34.41 | -17.00 |
| EPS Diluted | 0.00 | -2.46 | -8.63 | -28.81 | -1.06K | -8.66 | -42.45 | -34.41 | -17.00 |
| Weighted Avg Shares Out | 0.00 | 31.12K | 29.51K | 27.35K | 11.30K | 6.30K | 7.80K | 6.64K | 2.96K |
| Weighted Avg Shares Out (Dil) | 0.00 | 31.12K | 29.51K | 27.35K | 11.30K | 6.30K | 7.80K | 6.64K | 2.96K |
Source: https://incomestatements.info
Category: Stock Reports